Abstract |
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific monoclonal antibodies. One of the reasons for the attractiveness of this approach is the different mode of action of these antibodies compared to chemotherapy: they can exert tumor-suppressive effects by at least three major mechanisms: an intrinsic cytotoxic activity, antibody-dependent cellular cytotoxicity (ADCC), and activation of complement-dependent cytolysis (CDC). These monoclonal antibodies can be applied in an unconjugated form or as a carrier of cytotoxic drugs or radioisotopes. The chimeric anti-CD20 antibody rituximab has a direct anti- lymphoma activity, and is highly active in indolent and aggressive lymphoma, in particular in combination with chemotherapy. The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). Another attractive approach is to link anti-CD20 antibodies to radioisotopes, thereby exploiting the radiosensitivity of malignant lymphomas: encouraging results were already presented for the yttrium-90-((90)Y-)labeled anti-CD20 antibody ibritumomab tiuxetan as well as for the iodine-131-((131)I-)labeled anti-CD20 antibody tositumomab.
|
Authors | Christian Buske, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann |
Journal | Medizinische Klinik (Munich, Germany : 1983)
(Med Klin (Munich))
Vol. 100
Issue 1
Pg. 14-24
(Jan 15 2005)
ISSN: 0723-5003 [Print] Germany |
Vernacular Title | Antikörpertherapie maligner Lymphome. |
PMID | 15654538
(Publication Type: Comparative Study, English Abstract, Journal Article, Review)
|
Chemical References |
- Antibodies, Bispecific
- Antibodies, Monoclonal
|
Topics |
- Antibodies, Bispecific
(immunology, therapeutic use)
- Antibodies, Monoclonal
(immunology, therapeutic use)
- Antibody-Dependent Cell Cytotoxicity
(immunology)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Clinical Trials as Topic
- Combined Modality Therapy
- Follow-Up Studies
- Humans
- Lymphoma, B-Cell
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy, immunology)
- Radioimmunotherapy
- Remission Induction
- Treatment Outcome
|